278 related articles for article (PubMed ID: 23043594)
41. Efficacy and tolerability of Creon for Children in infants and toddlers with pancreatic exocrine insufficiency caused by cystic fibrosis: an open-label, single-arm, multicenter study.
Colombo C; Fredella C; Russo MC; Faelli N; Motta V; Valmarana L; Longo L; D'Orazio C
Pancreas; 2009 Aug; 38(6):693-9. PubMed ID: 19531972
[TBL] [Abstract][Full Text] [Related]
42. A double-blind, randomized, multicentre, crossover study to prove equivalence of pancreatin minimicrospheres versus microspheres in exocrine pancreatic insufficiency.
Halm U; Löser C; Löhr M; Katschinski M; Mössner J
Aliment Pharmacol Ther; 1999 Jul; 13(7):951-7. PubMed ID: 10383531
[TBL] [Abstract][Full Text] [Related]
43. A Retrospective Real-World Evidence Evaluation of the Characteristics of Exocrine Pancreatic Insufficiency in Patients With Chronic Pancreatitis and Type 2 Diabetes Treated With Pancrelipase in the United States.
Rosenberg J; Reddy MN; Seelam P; Li O; Twal J; Pack J
Pancreas; 2022 Nov-Dec 01; 51(10):1308-1314. PubMed ID: 37099771
[TBL] [Abstract][Full Text] [Related]
44. Fecal fat and energy loss in pancreas exocrine insufficiency: the role of pancreas enzyme replacement therapy.
Erchinger F; Øvre AKN; Aarseth MM; Engjom T; Brønstad I; Dimcevski G; Gudbrandsen OA; Tjora E
Scand J Gastroenterol; 2018 Sep; 53(9):1132-1138. PubMed ID: 30193081
[TBL] [Abstract][Full Text] [Related]
45. Impact of the treatment of pancreatic exocrine insufficiency on survival of patients with unresectable pancreatic cancer: a retrospective analysis.
Domínguez-Muñoz JE; Nieto-Garcia L; López-Díaz J; Lariño-Noia J; Abdulkader I; Iglesias-Garcia J
BMC Cancer; 2018 May; 18(1):534. PubMed ID: 29728096
[TBL] [Abstract][Full Text] [Related]
46. Safety and tolerability of a new formulation of pancrelipase delayed-release capsules (CREON) in children under seven years of age with exocrine pancreatic insufficiency due to cystic fibrosis: an open-label, multicentre, single-treatment-arm study.
Graff GR; McNamara J; Royall J; Caras S; Forssmann K
Clin Drug Investig; 2010; 30(6):351-64. PubMed ID: 20441244
[TBL] [Abstract][Full Text] [Related]
47. The effect of oral pancreatic enzyme supplementation on the course and outcome of acute pancreatitis: a randomized, double-blind parallel-group study.
Kahl S; Schütte K; Glasbrenner B; Mayerle J; Simon P; Henniges F; Sander-Struckmeier S; Lerch MM; Malfertheiner P
JOP; 2014 Mar; 15(2):165-74. PubMed ID: 24618443
[TBL] [Abstract][Full Text] [Related]
48. Summary and recommendations from the Australasian guidelines for the management of pancreatic exocrine insufficiency.
; Smith RC; Smith SF; Wilson J; Pearce C; Wray N; Vo R; Chen J; Ooi CY; Oliver M; Katz T; Turner R; Nikfarjam M; Rayner C; Horowitz M; Holtmann G; Talley N; Windsor J; Pirola R; Neale R
Pancreatology; 2016; 16(2):164-80. PubMed ID: 26775768
[TBL] [Abstract][Full Text] [Related]
49. Contribution of pancreatic enzyme replacement therapy to survival and quality of life in patients with pancreatic exocrine insufficiency.
Layer P; Kashirskaya N; Gubergrits N
World J Gastroenterol; 2019 May; 25(20):2430-2441. PubMed ID: 31171887
[TBL] [Abstract][Full Text] [Related]
50. Dependence of PERT endpoint on endogenous lipase activity.
Gao WY; Mulberg AE
Pancreas; 2014 Nov; 43(8):1232-8. PubMed ID: 25102439
[TBL] [Abstract][Full Text] [Related]
51. Efficacy of a novel pancreatic enzyme product, EUR-1008 (Zenpep), in patients with exocrine pancreatic insufficiency due to chronic pancreatitis.
Toskes PP; Secci A; Thieroff-Ekerdt R;
Pancreas; 2011 Apr; 40(3):376-82. PubMed ID: 21343835
[TBL] [Abstract][Full Text] [Related]
52. Differences in In Vitro Properties of Pancreatin Preparations for Pancreatic Exocrine Insufficiency as Marketed in Russia and CIS.
Maev IV; Kucheryavyy YA; Gubergrits NB; Bonnacker I; Shelest EA; Janssen-van Solingen GP; Domínguez-Muñoz JE
Drugs R D; 2020 Dec; 20(4):369-376. PubMed ID: 33211277
[TBL] [Abstract][Full Text] [Related]
53. Creon 10,000 Minimicrospheres vs. Creon 8,000 microspheres--an open randomised crossover preference study.
Patchell CJ; Desai M; Weller PH; Macdonald A; Smyth RL; Bush A; Gilbody JS; Duff SA
J Cyst Fibros; 2002 Dec; 1(4):287-91. PubMed ID: 15463829
[TBL] [Abstract][Full Text] [Related]
54. The use of pancreatic enzyme replacement therapy in patients with a diagnosis of chronic pancreatitis and pancreatic cancer in the US is infrequent and inconsistent.
Forsmark CE; Tang G; Xu H; Tuft M; Hughes SJ; Yadav D
Aliment Pharmacol Ther; 2020 May; 51(10):958-967. PubMed ID: 32249970
[TBL] [Abstract][Full Text] [Related]
55. Osteoporosis and sarcopenia are common and insufficiently diagnosed among chronic pancreatitis patients.
Parhiala M; Ukkonen M; Sand J; Laukkarinen J
BMC Gastroenterol; 2023 Apr; 23(1):124. PubMed ID: 37046204
[TBL] [Abstract][Full Text] [Related]
56. Pancreatic Enzyme Replacement Therapy in Patients with Non-pancreatic Digestive Conditions: A Nationwide Claims Analysis.
Phillips AE; Tang G; Wang X; Forsmark CE; Yadav D
Dig Dis Sci; 2023 May; 68(5):1754-1761. PubMed ID: 36370243
[TBL] [Abstract][Full Text] [Related]
57. A Multicenter Open-Label Randomized Controlled Trial of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer.
Saito T; Nakai Y; Isayama H; Hirano K; Ishigaki K; Hakuta R; Takeda T; Saito K; Umefune G; Akiyama D; Watanabe T; Takagi K; Takahara N; Hamada T; Uchino R; Mizuno S; Mouri D; Yagioka H; Kogure H; Togawa O; Matsubara S; Ito Y; Yamamoto N; Tada M; Koike K
Pancreas; 2018 Aug; 47(7):800-806. PubMed ID: 29851751
[TBL] [Abstract][Full Text] [Related]
58. Qualitative Assessment of the Symptoms and Impact of Pancreatic Exocrine Insufficiency (PEI) to Inform the Development of a Patient-Reported Outcome (PRO) Instrument.
Johnson CD; Arbuckle R; Bonner N; Connett G; Dominguez-Munoz E; Levy P; Staab D; Williamson N; Lerch MM
Patient; 2017 Oct; 10(5):615-628. PubMed ID: 28332032
[TBL] [Abstract][Full Text] [Related]
59. Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency: when is it indicated, what is the goal and how to do it?
Domínguez-Muñoz JE
Adv Med Sci; 2011; 56(1):1-5. PubMed ID: 21450558
[TBL] [Abstract][Full Text] [Related]
60. Pancreatic Exocrine Insufficiency in Type 1 and 2 Diabetes: Therapeutic Implications.
Talukdar R; Reddy DN
J Assoc Physicians India; 2017 Sep; 65(9):64-70. PubMed ID: 29313579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
